整合PET-MRI用于胶质瘤监测:灌注-代谢不一致率及其与分子分型的关联
研究纳入41例高级别胶质瘤患者,用整合3-T PET-MRI同步采集FDG PET与DCE灌注MRI,评估两种方法判断肿瘤进展的不一致率及肿瘤遗传学能否预测不一致。FDG PET与DCE-MRI诊断准确性相当,但27%患者结果不一致;肿瘤分级、体积、贝伐珠单抗暴露和放疗后时间可预测不一致,加入IDH及RTK通路突变后ROC AUC由0.78升至0.83。
要点
- FDG PET与DCE-MRI诊断肿瘤进展的敏感性分别为94%和91%,特异性分别为56%和89%。
- 27%的患者FDG PET与DCE-MRI结果不一致,其中DCE-MRI判断正确者占55%。
- 肿瘤分级、体积、贝伐珠单抗暴露及放疗后时间可预测不一致,加入IDH和RTK通路突变后AUC升至0.83。
核心结论
- FDG PET与DCE-MRI识别肿瘤进展的准确性和敏感性相当,超过四分之一患者两者结果不一致;肿瘤遗传学可能参与灌注-代谢不一致,原文认为需进一步研究。
研究设计与样本
- 连续纳入41例高级别胶质瘤患者(20例IV级、21例III级),采用整合3-T PET-MRI扫描仪按标准化肿瘤方案同步采集FDG PET与DCE灌注MRI,从分割的全肿瘤感兴趣区和靶ROI获取标准化摄取值、血浆容量和渗透性定量指标,以ROC曲线和约登指数确定最佳截断值,用2×2列联表和一致率评估准确性及一致性;26例(63%)患者接受下一代测序。
诊断标准与关键数值
- FDG PET最佳截断值诊断肿瘤进展的敏感性94%、特异性56%、准确性80%;DCE-MRI最佳截断值敏感性91%、特异性89%、准确性83%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文结论指出肿瘤遗传学可能参与灌注-代谢不一致,需进一步研究(warranting further investigation)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Both 18F-FDG PET and perfusion MRI are commonly used techniques for posttreatment glioma surveillance. Using integrated PET-MRI, we assessed the rate of discordance between simultaneously acquired FDG PET images and dynamic contrast-enhanced (DCE) perfusion MR images and determined whether tumor genetics predicts discordance.
MATERIALS AND METHODS: Forty-one consecutive patients with high-grade gliomas (20 with grade IV gliomas and 21 with grade III gliomas) underwent a standardized tumor protocol performed using an integrated 3-T PET-MRI scanner. Quantitative measures of standardized uptake value, plasma volume, and permeability were obtained from segmented whole-tumor volumes of interest and targeted ROIs. ROC curve analysis and the Youden index were used to identify optimal cutoffs for FDG PET and DCE-MRI. Two-by-two contingency tables and percent agreement were used to assess accuracy and concordance. Twenty-six patients (63%) from the cohort underwent next-generation sequencing for tumor genetics.
RESULTS: The best-performing FDG PET and DCE-MRI cutoffs achieved sensitivities of 94% and 91%, respectively; specificities of 56% and 89%, respectively; and accuracies of 80% and 83%, respectively. FDG PET and DCE-MRI findings were discordant for 11 patients (27%), with DCE-MRI findings correct for six of these patients (55%). Tumor grade, tumor volume, bevacizumab exposure, and time since radiation predicted discordance between FDG PET and DCE-MRI findings, with an ROC AUC value of 0.78. Isocitrate dehydrogenase gene and receptor tyrosine kinase gene pathway mutations increased the ROC AUC value to 0.83.
CONCLUSION: FDG PET and DCE-MRI show comparable accuracy and sensitivity in identifying tumor progression. These modalities were shown to have discordant findings for more than a quarter of the patients assessed. Tumor genetics may contribute to perfusion-metabolism discordance, warranting further investigation.
引用
- Seligman L, Kovanlikaya I, Pisapia DJ, et al. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling. AJR Am J Roentgenol. 2019. PMID: 30779663. doi:10.2214/AJR.18.20531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。